fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Trial Profile

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs ACP 001 (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Registrational
  • Acronyms fliGHt
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 06 Oct 2017 Status changed from planning to not yet recruiting.
    • 25 Aug 2017 New trial record
    • 18 Aug 2017 According to an Ascendis Pharma A/S media release, the company is prepared to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top